{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:35:47Z","timestamp":1792290947717,"version":"4.4.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hoc.2026.05.006","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:55:16Z","timestamp":1781726116000},"page":"619-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Therapy for Biliary and Liver Neoplasms"],"prefix":"10.1016","volume":"40","author":[{"given":"Ronan","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.hoc.2026.05.006_bib1","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.3748\/wjg.v23.i29.5282","article-title":"From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world","volume":"23","author":"Dimitroulis","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.006_bib2","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.006_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114018","article-title":"Clinical care pathways of patients with biliary tract cancer: a French nationwide longitudinal cohort study","volume":"202","author":"Tzedakis","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.006_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/HEP.0000000000000760","article-title":"Neoadjuvant and adjuvant therapy for biliary tract cancer: advances and limitations","volume":"82","author":"Wilbur","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.006_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.006_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.006_bib9","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1200\/JCO.2024.42.16_suppl.4119","article-title":"Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202\/ASCOT","volume":"42","author":"Nakachi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2026.05.006_bib10","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"Swog S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.006_bib11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"issue":"4_suppl","key":"10.1016\/j.hoc.2026.05.006_bib12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2025.43.4_suppl.570","article-title":"Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: a phase II, multicenter, randomized controlled trial (ACCORD trial)","volume":"43","author":"Kuang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.006_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S2468-1253(25)00268-7","article-title":"Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial","volume":"11","author":"Wang","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.006_bib14","doi-asserted-by":"crossref","first-page":"TPS4199","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4199","article-title":"A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-biliary01","volume":"42","author":"Fan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104540","article-title":"Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision medicine)","volume":"10","author":"Malka","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.006_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32100584","article-title":"Neoadjuvant strategies for patients with resectable biliary tract cancers: a review","volume":"32","author":"Olson","year":"2025","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.006_bib17","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hpb.12082","article-title":"Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience","volume":"16","author":"Duignan","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.hoc.2026.05.006_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1390","article-title":"97P neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): results of a randomized, multicenter, open-label, phase II trial (DEBATE)","volume":"34","author":"Yoo","year":"2023","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.006_bib20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.006_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.006_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114196","article-title":"Multicenter phase I\/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer","volume":"207","author":"Pressiani","year":"2024","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.006_bib25","doi-asserted-by":"crossref","first-page":"S564","DOI":"10.1016\/j.annonc.2022.07.082","volume":"33","author":"Lamarca","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2026.05.006_bib26","doi-asserted-by":"crossref","first-page":"S564","DOI":"10.1016\/j.annonc.2022.07.082","volume":"33","author":"Lamarca","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.006_bib27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal Irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.006_bib30","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.006_bib31","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.006_bib32","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.hoc.2026.05.006_bib33","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.006_bib34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41392-025-02356-y","article-title":"First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study","volume":"10","author":"Shi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.hoc.2026.05.006_bib36","volume":"35","author":"Ikeda","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.006_bib37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.006_bib38","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.006_bib40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.006_bib41","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.1016\/j.annonc.2022.07.087","article-title":"59P efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications","volume":"33","author":"Borad","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.006_bib44","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.006_bib45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.006_bib46","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.006_bib47","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.006_bib48","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.006_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.006_bib50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","volume":"82","author":"Hwang","year":"2025","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.006_bib51","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/1078-0432.CCR-23-1926","article-title":"Comparative genomic analysis and clinical outcomes of BRAF-mutated advanced biliary tract cancers","volume":"29","author":"Tang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.006_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Parisi","year":"2024","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.006_bib53","first-page":"4009","article-title":"Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors","volume":"41","author":"Goyal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"10.1016\/j.hoc.2026.05.006_bib54","doi-asserted-by":"crossref","first-page":"TPS575","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS575","article-title":"First-308: phase III study of tinengotinib versus physician\u2019s choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor\u2013refractory\/relapsed cholangiocarcinoma","volume":"42","author":"Javle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11523-022-00933-7","article-title":"Clinical outcomes after progression on first-line therapies in IDH1 mutated versus wild-type intrahepatic cholangiocarcinoma patients","volume":"18","author":"Rimini","year":"2023","journal-title":"Target Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.006_bib56","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9840","article-title":"KRAS allelic variants in biliary tract cancers","volume":"7","author":"Moffat","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf094","article-title":"MDM2 as a therapeutic target in advanced biliary tract cancers","volume":"30","author":"Spencer","year":"2025","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.006_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072105","article-title":"Precision oncology targets in biliary tract cancer","volume":"15","author":"Farha","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: a promising actionable target in biliary tract cancers","volume":"10","author":"Angerilli","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.006_bib61","article-title":"Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer","volume":"6","author":"Wan","year":"2025","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.006_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2019.11.016","article-title":"The chances of hepatic resection curing hepatocellular carcinoma","volume":"72","author":"Cucchetti","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.006_bib64","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.006_bib65","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1111\/j.1600-6143.2007.01965.x","article-title":"Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging","volume":"7","author":"Yao","year":"2007","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.adro.2015.12.003","article-title":"Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma","volume":"1","author":"Mohamed","year":"2016","journal-title":"Adv Radiat Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.006_bib67","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib68","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2024.01.011","article-title":"Immunotherapy and transplantation for hepatocellular carcinoma","volume":"80","author":"Tabrizian","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib69","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.006_bib70","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","article-title":"Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics","volume":"46","author":"Varela","year":"2007","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib71","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.006_bib72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000543245","article-title":"Lenvatinib plus pembrolizumab combined with transarterial chemoembolization in intermediate-stage hepatocellular carcinoma","volume":"14","author":"Kudo","year":"2025","journal-title":"Liver Cancer"},{"issue":"10474","key":"10.1016\/j.hoc.2026.05.006_bib74","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.006_bib75","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.006_bib76","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semradonc.2019.08.005","article-title":"Transarterial radioembolization for hepatocellular carcinoma and hepatic metastases: clinical aspects and dosimetry models","volume":"30","author":"Mikell","year":"2020","journal-title":"Semin Radiat Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.006_bib78","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.006_bib79","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","article-title":"Outcomes following definitive stereotactic body radiotherapy for patients with child-pugh B or C hepatocellular carcinoma","volume":"111","author":"Culleton","year":"2014","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.006_bib80","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/hepr.12359","article-title":"Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies","volume":"45","author":"Kimura","year":"2015","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib81","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00261-022-03690-3","article-title":"Stereotactic body radiation therapy versus radiofrequency ablation in hepatocellular carcinoma: an up-date meta-analysis","volume":"48","author":"Yang","year":"2023","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib82","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib83","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/s12885-024-12504-2","article-title":"A randomised controlled trial of standard of care versus RadioAblaTion in early stage HepatoCellular carcinoma (SOCRATES HCC)","volume":"24","author":"Wigg","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.006_bib84","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib85","first-page":"498","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians","volume":"75","author":"Moris","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib86","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","article-title":"Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","volume":"68","author":"Pinyol","year":"2019","journal-title":"Gut"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.006_bib87","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/fon-2020-0162","article-title":"IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation","volume":"16","author":"Hack","year":"2020","journal-title":"Future Oncol"},{"issue":"10415","key":"10.1016\/j.hoc.2026.05.006_bib88","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.006_bib89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.006_bib90","article-title":"Evolving landscape in liver transplantation for hepatocellular carcinoma: from stage migration to immunotherapy revolution","volume":"13","author":"Cesario","year":"2023","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib91","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/era.09.41","article-title":"Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial","volume":"9","author":"Rimassa","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.006_bib92","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10126","key":"10.1016\/j.hoc.2026.05.006_bib94","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.hoc.2026.05.006_bib95","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib96","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"10088","key":"10.1016\/j.hoc.2026.05.006_bib97","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.006_bib98","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.006_bib99","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (checkMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.006_bib101","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.006_bib102","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"4_suppl","key":"10.1016\/j.hoc.2026.05.006_bib103","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.006_bib104","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.006_bib105","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10408","key":"10.1016\/j.hoc.2026.05.006_bib106","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"10492","key":"10.1016\/j.hoc.2026.05.006_bib107","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (checkMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.006_bib108","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2217\/fon-2019-0097","article-title":"RATIONALE 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"15","author":"Qin","year":"2019","journal-title":"Future Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.006_bib109","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.006_bib110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.006_bib111","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.006_bib112","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","article-title":"From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma","volume":"38","author":"Fu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.006_bib113","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.006_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112708","article-title":"Biomarkers in hepatobiliary cancers: what is useful in clinical practice?","volume":"13","author":"Boil\u00e8ve","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.006_bib115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg Nutr"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:31:28Z","timestamp":1784579488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0889858826000468"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy for Biliary and Liver Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}